tradingkey.logo

ANI Pharmaceuticals Inc

ANIP
View Detailed Chart

97.480USD

+2.125+2.23%
Close 09/18, 16:00ETQuotes delayed by 15 min
2.12BMarket Cap
LossP/E TTM

ANI Pharmaceuticals Inc

97.480

+2.125+2.23%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.23%

5 Days

-1.27%

1 Month

+8.66%

6 Months

+51.79%

Year to Date

+76.34%

1 Year

+59.67%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
9 / 175
Overall Ranking
62 / 4721
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 8 analysts
Buy
Current Rating
103.571
Target Price
+8.62%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 94.19% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD 20.15M.%!(EXTRA int=2)
Undervalued
The company’s latest PE is -142.53, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 24.45M shares, decreasing 4.47% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.27M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.66.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products.
Ticker SymbolANIP
CompanyANI Pharmaceuticals Inc
CEOMr. Nikhil Suresh Lalwani
Websitehttps://www.anipharmaceuticals.com/
KeyAI